
RTN4 AND FBXL17 GENES ARE ASSOCIATED WITH
CORONARY HEART DISEASE IN GENOME-WIDE
ASSOCIATION ANALYSIS OF LITHUANIAN FAMILIES Domarkienė I1,*, Pranculis A1, Germanas Š1, Jakaitienė A1,
Vitkus D2, Dženkevičiūtė V3, Kučinskienė ZA2, Kučinskas V1 *Corresponding Author: Ingrida Domarkienė, Department of Human and Medical Genetics, Faculty of Medicine,
Vilnius University, Santariškių str. 2, 08661 Vilnius, Lithuania; Tel.: +370-52501788; E-mail: ingrida.domarkiene@
mf.vu.lt page: 17
|
RESULTS
According to the Illumina Inc. protocol guidelines,
all of the samples except one, were of good
quality and had been properly processed (call rate
>98; LogRDev <0.3; coincidental sex list file created).
At the beginning of the analysis there were 731,412
SNPs genotyped in the group of 96 individuals. After
the data filtering procedure, two individuals were
removed from further analysis for low genotyping
(MIND >0.05); 25,293 heterozygous genotypes were
excluded from analysis because the second allele of the
genotype was missing; 298 SNPs were excluded based
on the Hardy-Weinberg equilibrium test (p >0.0005);
2528 SNPs failed missingness test (GENO >0.1);
82,552 SNPs failed frequency test (MAF <0.01); 591
SNP were not used because of homogeneity over all
individuals. After the final frequency and genotyping
pruning, 646,445 SNPs in 31 patient and 63 parents
were included for further association analysis.
Twelve SNPs were found to be significantly associated
with CHD phenotype with p values smaller
than 0.0001. The SNPs annotation (transmitted allele,
chromosomal position, gene, gene function) along
with the c2, p value, OR and empirical power based
on the sample size calculations, are presented in Table
1. The SNPs are annotated according to the National
Center for Biotechnology Information (NCBI) dbSNP
and Gene databases [9].
The acceptable power values were greater than
or equal to 0.65, and thus fell partly into the desired
range between 0.8 and 0.95 [10]. Only the power
value of the significant SNP rs1321936 diverged and
was excluded from further evaluation.
The OR values in Table 1 show the size of the
effect. The greater the deviation of OR is from the
value of 1, the more significant the test is.
As can be seen from the Manhattan plot (Figure
1), there are three significant markers (rs12734338,
rs3883013, rs3853444) that do not have the significant
adjacent SNPs (according to the nucleotide’s position),
i.e., the correlation is absent. Thus, these markers
could be artefacts. We could also suspect that not
all of the adjacent SNPs were genotyped. This is more
likely to happen with rs3853444, as there were two
adjacent SNPs that were excluded from the analysis.
It was previously mentioned that the study group
included only male patients and their parents. A male
could possess the SNP allele on either his X or Y
chromosome and this affects the analysis algorithm.
Each transmission from a heterozygous mother to a
male offspring should be given twice the weight of
a transmission to a female offspring [11]. Thus, the
standard TDT appears to be unsuitable for the analysis
of SNPs in sex chromosomes and eventually sex
chromosomes were excluded from the analysis.
|
|
|
|



 |
Number 27 VOL. 27 (2), 2024 |
Number 27 VOL. 27 (1), 2024 |
Number 26 Number 26 VOL. 26(2), 2023 All in one |
Number 26 VOL. 26(2), 2023 |
Number 26 VOL. 26, 2023 Supplement |
Number 26 VOL. 26(1), 2023 |
Number 25 VOL. 25(2), 2022 |
Number 25 VOL. 25 (1), 2022 |
Number 24 VOL. 24(2), 2021 |
Number 24 VOL. 24(1), 2021 |
Number 23 VOL. 23(2), 2020 |
Number 22 VOL. 22(2), 2019 |
Number 22 VOL. 22(1), 2019 |
Number 22 VOL. 22, 2019 Supplement |
Number 21 VOL. 21(2), 2018 |
Number 21 VOL. 21 (1), 2018 |
Number 21 VOL. 21, 2018 Supplement |
Number 20 VOL. 20 (2), 2017 |
Number 20 VOL. 20 (1), 2017 |
Number 19 VOL. 19 (2), 2016 |
Number 19 VOL. 19 (1), 2016 |
Number 18 VOL. 18 (2), 2015 |
Number 18 VOL. 18 (1), 2015 |
Number 17 VOL. 17 (2), 2014 |
Number 17 VOL. 17 (1), 2014 |
Number 16 VOL. 16 (2), 2013 |
Number 16 VOL. 16 (1), 2013 |
Number 15 VOL. 15 (2), 2012 |
Number 15 VOL. 15, 2012 Supplement |
Number 15 Vol. 15 (1), 2012 |
Number 14 14 - Vol. 14 (2), 2011 |
Number 14 The 9th Balkan Congress of Medical Genetics |
Number 14 14 - Vol. 14 (1), 2011 |
Number 13 Vol. 13 (2), 2010 |
Number 13 Vol.13 (1), 2010 |
Number 12 Vol.12 (2), 2009 |
Number 12 Vol.12 (1), 2009 |
Number 11 Vol.11 (2),2008 |
Number 11 Vol.11 (1),2008 |
Number 10 Vol.10 (2), 2007 |
Number 10 10 (1),2007 |
Number 9 1&2, 2006 |
Number 9 3&4, 2006 |
Number 8 1&2, 2005 |
Number 8 3&4, 2004 |
Number 7 1&2, 2004 |
Number 6 3&4, 2003 |
Number 6 1&2, 2003 |
Number 5 3&4, 2002 |
Number 5 1&2, 2002 |
Number 4 Vol.3 (4), 2000 |
Number 4 Vol.2 (4), 1999 |
Number 4 Vol.1 (4), 1998 |
Number 4 3&4, 2001 |
Number 4 1&2, 2001 |
Number 3 Vol.3 (3), 2000 |
Number 3 Vol.2 (3), 1999 |
Number 3 Vol.1 (3), 1998 |
Number 2 Vol.3(2), 2000 |
Number 2 Vol.1 (2), 1998 |
Number 2 Vol.2 (2), 1999 |
Number 1 Vol.3 (1), 2000 |
Number 1 Vol.2 (1), 1999 |
Number 1 Vol.1 (1), 1998 |
|
|